FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment
Go back to FDA Approves Glaxo's Raxibacumab as Inhalational Anthrax Treatment| GLAXOSMITHKLINE PLC (NYSE: GSK) | Delayed: 40.91 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $40.91 | 52 Week High | $45.58 | |||
| Open | $40.91 | 52 Week Low | $37.82 | |||
| Day High | $40.91 | P/E | N/A | |||
| Day Low | $40.91 | EPS | $0.00 | |||
| Volume | 507 | |||||
